Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05133635
Other study ID # Steroid/Toci COVID-19
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date February 1, 2021
Est. completion date April 1, 2021

Study information

Verified date November 2021
Source Marmara University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COVID-19 pandemic has spread all over the world, and hospitalization of the patients with COVÄ°D-19 Pneumonia has become a great burden to the Intensive Care Units. Unfortunately there is still no curative method for the disease yet. Intensive Care Units provide general care for the patients; including oxygen therapy, maintenance of the organ systems (e.g., cardiovascular, renal), nutrition, antibiotic therapy for secondary infections, and etc. One of the major problems in COVID-19 is macrophage activation syndrome, also known as cytokine storm. It stems from exaggerated inflammatory response, which causes increased cytokine release and results in clinical deterioration of the patients. Many drugs have been used to prevent this exaggerated inflammation, like corticosteroids, interleukin (IL) receptor blockers, plasma exchange, etc. In this study our aim is to investigate the effectiveness of high dose corticosteroid (methylprednisolone 250 mg for 3 days) and an IL-6 receptor antagonist (tocilizumab) in the treatment of the cytokine storm of the COVID-19 patients.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 1, 2021
Est. primary completion date April 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients with COVID-19 Pneumonia treated in the Intensive Care Unit - Clinical deterioration during intensive care follow-up - First 14 days from the COVID-19 diagnosis Exclusion Criteria: - More than 14 days passed from the COVID-19 diagnosis - Clinical and laboratory signs of secondary bacterial infection

Study Design


Intervention

Drug:
Methylprednisolone
Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
Tocilizumab
Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Marmara University

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical condition Arterial oxygen partial pressure of the patient will be observed. Next 7 days of the intervention.
Primary Blood analysis Acute phase reactants (C-reactive protein, procalcitonin, ferritin, fibrinogen), will be investigated. Next 7 days of the intervention.
Secondary Hospital stay Hospital stay period of the patients will be observed. Until the hospital discharge.
Secondary Mortality Mortality of the patients will be observed. Not relevant
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Recruiting NCT05491304 - Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis Phase 4
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT05307601 - Immune Response Following COVID-19 in Hemodialysis Patients
Completed NCT04476745 - The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People N/A
Completed NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine N/A
Completed NCT01302223 - Keratinocyte Growth Factor and Cytokines in Burns. N/A
Completed NCT04483271 - The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm N/A
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Completed NCT04910893 - Cytokine Adsorption in Severe, Refractory Septic Shock N/A
Completed NCT04854252 - Inflammatory Response to Opioid Versus Opioid Free Anesthesia N/A
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT04377308 - Fluoxetine to Reduce Intubation and Death After COVID19 Infection Phase 4
Completed NCT04324528 - Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT05476848 - Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 Patients N/A
Completed NCT04913298 - Prospective Study for the Application of Cytosorb® in Critically Ill Patients N/A
Recruiting NCT04753476 - Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia Phase 2
Terminated NCT04327505 - Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 Phase 2/Phase 3
Withdrawn NCT04433078 - RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM Phase 2